SI2556090T1 - Protitelesa in testi topnega človeškega ST-2 - Google Patents

Protitelesa in testi topnega človeškega ST-2

Info

Publication number
SI2556090T1
SI2556090T1 SI201130795A SI201130795A SI2556090T1 SI 2556090 T1 SI2556090 T1 SI 2556090T1 SI 201130795 A SI201130795 A SI 201130795A SI 201130795 A SI201130795 A SI 201130795A SI 2556090 T1 SI2556090 T1 SI 2556090T1
Authority
SI
Slovenia
Prior art keywords
assays
antibodies
soluble human
soluble
human
Prior art date
Application number
SI201130795A
Other languages
English (en)
Inventor
James V. Snider
Original Assignee
Critical Care Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics, Inc. filed Critical Critical Care Diagnostics, Inc.
Publication of SI2556090T1 publication Critical patent/SI2556090T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
SI201130795A 2010-04-09 2011-04-08 Protitelesa in testi topnega človeškega ST-2 SI2556090T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32257810P 2010-04-09 2010-04-09
US34583710P 2010-05-18 2010-05-18
EP11766825.1A EP2556090B1 (en) 2010-04-09 2011-04-08 Soluble human st-2 antibodies and assays
PCT/US2011/031801 WO2011127412A2 (en) 2010-04-09 2011-04-08 Soluble human st-2 antibodies and assays

Publications (1)

Publication Number Publication Date
SI2556090T1 true SI2556090T1 (sl) 2016-07-29

Family

ID=44763578

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130795A SI2556090T1 (sl) 2010-04-09 2011-04-08 Protitelesa in testi topnega človeškega ST-2

Country Status (19)

Country Link
US (4) US8420785B2 (sl)
EP (4) EP3848394A1 (sl)
JP (5) JP5635180B2 (sl)
CN (2) CN106620692B (sl)
AU (1) AU2011237359B2 (sl)
BR (1) BR112012025728B1 (sl)
CA (1) CA2795200C (sl)
DK (1) DK2556090T3 (sl)
ES (3) ES2571994T3 (sl)
HR (1) HRP20160461T1 (sl)
HU (1) HUE027760T2 (sl)
IL (2) IL222276B (sl)
MX (3) MX2012011667A (sl)
PL (1) PL2556090T3 (sl)
RS (1) RS54762B1 (sl)
RU (3) RU2684724C2 (sl)
SG (2) SG10201704453YA (sl)
SI (1) SI2556090T1 (sl)
WO (1) WO2011127412A2 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
US7998683B2 (en) 2006-04-24 2011-08-16 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
EP2021796B1 (en) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PT2019965E (pt) * 2006-05-02 2015-08-28 Critical Care Diagnostics Inc Diagnóstico diferencial entre doença pulmonar e cardiovascular
WO2009129454A2 (en) 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
EP3848394A1 (en) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
GB201013151D0 (en) * 2010-08-04 2010-09-22 Isis Innovation Diagnostic method
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
BR112014001283A2 (pt) 2011-07-18 2017-02-21 Critical Care Diagnostics Inc métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
EP3434260A1 (en) * 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
CN105785028A (zh) * 2012-08-10 2016-07-20 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
RU2683026C2 (ru) * 2012-08-16 2019-03-26 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
CN104737170A (zh) * 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和***
CN103926406A (zh) * 2014-04-29 2014-07-16 安徽省立医院 一种指示肝炎感染的标志物及其用途
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN107209175B (zh) * 2014-12-11 2019-09-17 重症监护诊断股份有限公司 用于st2心脏生物标志物的测试装置和方法
US10324089B2 (en) * 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN105259353B (zh) * 2015-10-15 2017-03-22 北京市心肺血管疾病研究所 一种主动脉瘤和/或主动脉夹层患者血液中可溶性st2的检测试剂盒及检测方法
CN107765014B (zh) * 2016-08-23 2019-11-19 上海费玛生物科技有限公司 一种检测人sST2蛋白的方法以及试剂盒
CN108956996A (zh) * 2017-05-23 2018-12-07 深圳市安群生物工程有限公司 检测人st2蛋白的荧光免疫层析试纸及其制备方法
CN107340386A (zh) * 2017-06-09 2017-11-10 厦门大学附属中山医院 基于微粒子化学发光免疫分析的sST2检测试剂盒
CN108152486A (zh) * 2017-12-22 2018-06-12 太原瑞盛生物科技有限公司 一种人可溶性st2的磁微粒化学发光检测试剂盒及制备方法
JP2022513406A (ja) * 2018-10-31 2022-02-07 デリニア インコーポレイテッド 多価制御性ｔ細胞調節因子
CN110208549A (zh) * 2019-07-01 2019-09-06 北京利德曼生化股份有限公司 一种可溶性生长刺激表达基因2蛋白sST2发光试剂盒
CN110357963B (zh) * 2019-07-31 2020-09-18 北京智仁美博生物科技有限公司 抗人st2抗体及其用途
CN111308086B (zh) * 2020-02-21 2022-02-25 苏州旭光科星抗体生物科技有限公司 一种检测可溶性st2含量的酶联免疫检测试剂盒及用途
CN111863259A (zh) * 2020-08-06 2020-10-30 复旦大学附属中山医院 基于sST2评价肿瘤免疫治疗相关性心肌炎的预后模型及其应用
CN112457392B (zh) * 2021-01-27 2021-04-27 天津奇云诺德生物医学有限公司 一种可溶性st2蛋白抗原决定簇多肽及其应用
CN112924697A (zh) * 2021-01-29 2021-06-08 中翰盛泰生物技术股份有限公司 sST2在CAP患者的预后风险预测中的用途
CN113912729B (zh) * 2021-12-08 2022-03-04 南京融捷康生物科技有限公司 针对sST2的单域抗体及其衍生蛋白和应用
CN114870001A (zh) * 2022-07-07 2022-08-09 北京市心肺血管疾病研究所 Il-33在制备预防和/或治疗主动脉夹层的药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE388694B (sv) 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5073484A (en) 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4743560A (en) 1984-03-26 1988-05-10 Becton Dickinson And Company Solid phase assay
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
JPS61122292A (ja) 1984-11-16 1986-06-10 Teijin Ltd 新規カルバサイクリン中間体の製法
DE3445816C1 (de) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flaechenfoermiges diagnostisches Mittel
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4855240A (en) 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
CA1313616C (en) 1987-06-01 1993-02-16 Robert B. Sargeant Lateral flow, non-bibulous membrane protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5229073A (en) 1992-02-27 1993-07-20 Abbott Laboratories One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a)
EP0831714A1 (en) 1995-06-07 1998-04-01 Merck & Co., Inc. Monospecific antibodies and methods using them
WO1997006439A1 (en) 1995-08-09 1997-02-20 Quidel Corporation Test strip and method for one step lateral flow assay
AU6277498A (en) 1997-02-15 1998-09-08 Beth Israel Deaconess Medical Center Multiple-site antibody capture immunoassays and kits
DE19711932A1 (de) * 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
GB9727172D0 (en) * 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
WO2004081047A1 (ja) * 2003-03-14 2004-09-23 Taisho Pharmaceutical Co., Ltd. モノクローナル抗体及びこれを産生するハイブリドーマ
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7998683B2 (en) 2006-04-24 2011-08-16 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
EP2021799B1 (en) 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
EP2021796B1 (en) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PT2019965E (pt) 2006-05-02 2015-08-28 Critical Care Diagnostics Inc Diagnóstico diferencial entre doença pulmonar e cardiovascular
US8865645B2 (en) 2006-05-24 2014-10-21 Biogen Idec Ma Inc. Method of treating lung fibrosis using ST2 polypeptide
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2009129454A2 (en) 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
EP2112149A1 (de) * 2008-04-22 2009-10-28 Bayer CropScience Aktiengesellschaft 2-[(1h-Pyrazol-4-ylmethyl)-sulfonyl]-Oxazol-Derivate, 2-[(1H-Pyrazol-4-ylmethyl)-sulfanyl]-Oxazol-Derivate und chirale 2-[(1H-Pyrazol-4-ylmethyl)-sulfinyl]-Oxazol-Derivate, Verfahren zu deren Herstellung sowie deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2010025393A2 (en) 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
JP5606535B2 (ja) 2009-09-09 2014-10-15 ハーマン、ミラー、インコーポレイテッド パーティションシステム
EP3848394A1 (en) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
BR112014001283A2 (pt) 2011-07-18 2017-02-21 Critical Care Diagnostics Inc métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
RU2683026C2 (ru) 2012-08-16 2019-03-26 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
CN104737170A (zh) * 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和***

Also Published As

Publication number Publication date
US9150654B2 (en) 2015-10-06
DK2556090T3 (en) 2016-05-30
CN106620692B (zh) 2021-04-09
JP2021092587A (ja) 2021-06-17
JP2019191199A (ja) 2019-10-31
HRP20160461T1 (hr) 2016-06-17
IL222276B (en) 2018-11-29
EP3434694B1 (en) 2020-12-30
CN103154027A (zh) 2013-06-12
EP3434694A1 (en) 2019-01-30
BR112012025728A2 (pt) 2020-09-01
IL222276A0 (en) 2012-12-31
JP2015091798A (ja) 2015-05-14
JP5635180B2 (ja) 2014-12-03
US20130177931A1 (en) 2013-07-11
US8420785B2 (en) 2013-04-16
RU2019109844A (ru) 2020-10-05
ES2571994T3 (es) 2016-05-27
MX2018013008A (es) 2022-02-15
RU2017121298A (ru) 2019-01-28
RU2684724C2 (ru) 2019-04-11
JP2017173337A (ja) 2017-09-28
MX360543B (es) 2018-10-24
JP6563976B2 (ja) 2019-08-21
US20110256635A1 (en) 2011-10-20
AU2011237359B2 (en) 2016-02-04
EP3050901B1 (en) 2018-08-29
CA2795200A1 (en) 2011-10-13
CN106620692A (zh) 2017-05-10
ES2699591T3 (es) 2019-02-11
JP7064034B2 (ja) 2022-05-09
EP2556090A2 (en) 2013-02-13
EP3050901A1 (en) 2016-08-03
ES2859577T3 (es) 2021-10-04
HUE027760T2 (en) 2016-11-28
CA2795200C (en) 2020-01-14
JP6849751B2 (ja) 2021-03-31
EP2556090B1 (en) 2016-02-24
BR112012025728B1 (pt) 2022-01-11
MX2012011667A (es) 2013-03-05
WO2011127412A3 (en) 2012-01-26
SG184450A1 (en) 2012-11-29
AU2011237359A1 (en) 2012-11-01
EP3848394A1 (en) 2021-07-14
JP6151676B2 (ja) 2017-06-21
JP2013523840A (ja) 2013-06-17
US10745484B2 (en) 2020-08-18
SG10201704453YA (en) 2017-07-28
RU2625014C2 (ru) 2017-07-11
EP2556090A4 (en) 2013-08-21
PL2556090T3 (pl) 2017-07-31
IL262649A (en) 2018-12-31
CN103154027B (zh) 2016-06-29
RU2012147638A (ru) 2014-05-27
WO2011127412A2 (en) 2011-10-13
US20150361177A1 (en) 2015-12-17
US20200339695A1 (en) 2020-10-29
RU2017121298A3 (sl) 2019-01-28
RS54762B1 (sr) 2016-10-31
IL262649B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL262649A (en) Soluble human ST – 2 antibodies and testing
HK1176948A1 (zh) 抗人 抗體及其用途
PL2946791T3 (pl) Przeciwciała anty-CD277 i ich zastosowania
IL225545A0 (en) Antibodies specific to cancerous tumors and their uses
LT3333188T (lt) Anti-ngf antikūnai ir jų panaudojimas
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
HK1182117A1 (zh) 抗生腱蛋白- 抗體及使用方法
EP2525813A4 (en) ANTIBODIES TO ILT5 AND ILT5 BINDING ANTIBODY FRAGMENTS
HK1209060A1 (en) Antibodies to endoplasmin and their use
HK1179981A1 (zh) 的抗體及其用途
ZA201302537B (en) Stable and soluble antibodies
EP2611832A4 (en) ANTI-CXCL13 ANTIBODIES AND METHOD FOR THEIR USE
ZA201307641B (en) Human tissue factor antibody and uses thereof
HK1209131A1 (en) Anti-alpha2 integrin antibodies and their uses -2
EP2632952A4 (en) ANTI-SOD1 ANTIBODIES AND USES THEREOF
EP2621955A4 (en) ANTI-CEACAM6 ANTIBODIES AND USES THEREOF
EP2593475A4 (en) ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY
EP2554552A4 (en) NOVEL ANTI-CD98 ANTIBODIES AND USE THEREOF
EP2620449A4 (en) EPIDINATED ANTIBODIES AGAINST B2 AND THE USE THEREOF
EP2545378A4 (en) ANTI-LG3 ANTIBODIES AND USES THEREOF
EP2578682A4 (en) ANTIBODIES AND ITS USE